Bausch Health to Face Investors Amid High-Stakes Debt Strategy

LAVAL, QC – February 17, 2026 – Bausch Health Companies Inc. is preparing for a pivotal engagement with the investment community as its top financial executives head to the J.P. Morgan Global Leveraged Finance Conference in early March. While the company's press release framed the attendance as a routine investor meeting, the context surrounding the event paints a picture of a company at a critical strategic juncture, navigating a complex financial landscape defined by substantial debt, looming patent expirations, and crucial pipeline developments.

Executive Vice President and CFO Jean-Jacques (JJ) Charhon will lead the management team in Miami Beach from March 2–4. Their primary audience will be a sophisticated group of credit analysts and investors who specialize in leveraged finance—a market Bausch Health knows intimately. The conference provides a crucial platform for management to articulate its strategy for financial stability and future growth, an essential task for a company working to manage its capital structure while investing in its future.

Navigating a Mountain of Debt

At the heart of investor discussions will be Bausch Health's formidable debt load. As of late 2024, the company carried approximately $21.5 billion in total debt, resulting in a high debt-to-capital ratio of 85% and a net debt-to-equity ratio that has ballooned in recent years. While its interest coverage ratio of 1.4x indicates earnings are just covering interest payments, the company has been aggressively proactive in managing its obligations.

In 2025, Bausch Health executed several significant liability management transactions. A major $7.9 billion refinancing in April successfully extended near- and medium-term debt maturities, providing critical breathing room. This was followed by a planned repayment of roughly $900 million in debt during the summer, utilizing cash on hand. These moves were part of a broader strategy to address the $2.6 billion of debt due in 2025 and subsequent maturities in 2026, which management has stated it can handle without seeking new funding, supported by a credit facility and strong free cash flow generation.

Despite this progress, the road ahead remains challenging. The company's stated ambition is to reach a more manageable leverage ratio of 4x with $8 billion in debt by 2028. Achieving this goal will require a delicate balance of using free cash flow, which has been robust, and potentially selling assets. Investors at the conference will be keen to hear detailed plans on how the company will continue to chip away at its debt, particularly with senior secured notes coming due in 2027.

The Xifaxan Countdown and Pipeline Pressures

Compounding the financial pressure is a significant operational challenge on the horizon: the patent exclusivity loss for its blockbuster drug, Xifaxan, expected in 2028. Xifaxan, a treatment for irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy, is the company's primary cash cow, accounting for approximately half of its EBITDA. The prospect of generic competition post-2028, coupled with potential pricing pressures from the Inflation Reduction Act as early as 2027, creates significant uncertainty around future earnings and the company's ability to service its debt long-term.

This makes the performance of Bausch Health's development pipeline more critical than ever. However, the company faced a significant setback in January 2026 with the announcement that its RED-C Phase 3 clinical trials for a key pipeline asset failed to meet their primary endpoints. This news puts additional pressure on management to demonstrate a viable path to growth that can offset the eventual decline of Xifaxan. Investors will undoubtedly press Mr. Charhon and his team for updates on other pipeline candidates and the company's business development strategy to acquire new, promising assets.

While facing these headwinds, the core business has shown resilience. Excluding the performance of its Bausch + Lomb segment, Bausch Health delivered its tenth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth in its most recent reporting period and raised its full-year 2025 guidance. This underlying operational strength will be a key talking point for management as they seek to build confidence in the company's ongoing viability.

The Bausch + Lomb Question

A central piece of the Bausch Health puzzle is its controlling 89% stake in Bausch + Lomb Corporation. The eye health giant has been a strong performer, reporting 6% organic revenue growth in the third quarter of 2025, driven by popular consumer brands like PreserVision, LUMIFY, and Blink. Strategically, Bausch + Lomb has also shored up its own finances, completing a refinancing in June 2025 that pushed its nearest debt maturities out to 2031, thereby de-risking a significant portion of the consolidated capital structure.

For years, investors have viewed a full separation of Bausch + Lomb as a clear path to unlocking significant shareholder value and providing Bausch Health with the means for a transformative debt reduction. Management has historically tied the timing of such a move to favorable market conditions and achieving specific deleveraging targets for the remaining company. The Miami conference will serve as an opportunity for investors to probe for any change in thinking or an updated timeline regarding the separation. Any signals from management on the future of this valuable asset will be scrutinized as a key indicator of the company's overarching strategic direction.

Ultimately, Bausch Health's presence at the J.P. Morgan conference is more than a simple check-in. It is a strategic imperative. The company finds itself in a position familiar to many in the pharmaceutical industry: balancing the servicing of legacy debt, often accumulated through past acquisitions, with the urgent need to fund innovation and navigate patent cliffs. Management's performance in Miami will be a crucial test of their ability to convince a skeptical market that they have a credible and sustainable plan to not only survive its financial challenges but to position the company for a prosperous future.